WASHINGTON, Sept. 6, 2002 (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. (OTCBB:SPHC), announced its CEO is a founding member of the CEO Council (www.ceocouncil.net), a newly formed non-profit association representing public companies.
Dr. Janet Greeson, Chairman, President and CEO and Eugene Boyle, CFO will represent Samaritan as members of the CEO Council. Dr. Greeson was also elected to the CEO Council's initial seven-member board of directors. Dr. Greeson stated, "It's a great honor to be a part of this meaningful organization. We look forward to the first Summit with great anticipation, especially the networking with other CEO's of public companies."
The mission of the CEO Council is to provide a common voice and platform for officers and directors of public companies, and enable them to more effectively interpret and participate in the corporate governing and regulatory process to ensure compliance, to safeguard shareholder value and to clearly demonstrate a dedication to fair and ethical business practices. Its motto titled "In the Public Interest."
The newly formed CEO Council membership is hosting its first annual CEO Summit on September 25, 2002 in The Great Hall of the historic Charles Sumner School Museum in Washington DC. More information about the CEO Council and the upcoming CEO Summit visit www.ceocouncil.net or contact Gerald N. Kern, 480-614-5324, jkern@ceocouncil.net
About Samaritan Pharmaceuticals
Samaritan Pharmaceuticals is an emerging biopharmaceutical company that has collaborated with Georgetown University to provide its research arm. We are dedicated to saving lives, by developing "breakthrough discovery" for Alzheimer's, Cancer, Cholesterol Reduction, HIV and Parkinson's. Samaritan's pipeline, includes one late stage Phase II HIV drug, an Alzheimer's and Breast Cancer Diagnostic, and has discovered nine drug candidates which are in various preclinical trials.
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 26, 2002. The company undertakes no duty to update forward-looking statements.
Note: To receive future press releases and newsletters automatically, or for more information, visit our Web site at www.samaritanpharmaceuticals.com.